Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 μg of OPN-375 Twice a Day (BID) in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps

NCT03960580 is registered in ClinicalTrials.gov with Optinose US Inc. as lead sponsor.

NCT NCT03960580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03960580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 μg of OPN-375 Twice a Day (BID) in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps
Lead sponsor
Optinose US Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 6, 2019
Completion date
May 4, 2022
Enrollment
223 (actual)
Sites
87

Conditions

As the registry lists them; a condition with its own page is linked.

chronic rhinosinusitis